Novartis Projects 5% Sales Growth Through 2031, Boosted by Key Brand Performance
Trendline

Novartis Projects 5% Sales Growth Through 2031, Boosted by Key Brand Performance

What's Happening? Novartis has updated its mid-term financial guidance, projecting a 5% compound annual growth rate (CAGR) in net sales through 2031. The pharmaceutical company also anticipates its core operating income margin to exceed 40% by 2029. This revised outlook, announced at the 'Meet Novar
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.